RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Neuro, Thanks.



Nicotinic programs -



http://en.wikipedia.org/wiki/Nicotinic_agonist



>>> Currently nicotine receptor agonist research and drug designing is aimed for treatment of multiple diseases and disorders of the CNS.

Targacept has four drug candidates that are in clinical trials; AZD3480 (TC-1734) for ADHD which is currently in phase II clinical trials and AZD1446 (TC-6683) for Alzheimers disease in collaboration with AstraZeneca, TC-5619 for cognitive dysfunctions in schizophrenia and TC-5214 as an augmentation treatment for major depressive disorder (MDD) in subjects who did not respond adequately to first-line treatment with citalopram hydrobromide.[37]

Memory Pharmaceuticals with its partner Roche has one drug candidate, MEM 3454 (RG3487), a partial agonist of the nicotinic a7 receptor, for Alzheimers disease.[38][39]

Abbott Laboratories in partnership with NeuroSearch have two drug candidates in clinical trials, ABT-894, a selective a4ß2 nicotine receptor agonist, for ADHD and ABT-560, a neuronal nicotinic receptor modulator, which was selected by Abbott in 2006 as a new development candidate for cognitive dysfunctions.[40]

EnVivo pharmaceuticals has one drug candidate in clinical trials, EVP-6124, a selective a7 nicotine receptor agonist for Alzheimer’s disease and schizophrenia and one follow-up compound, EVP-4473, that has successfully completed pre-clinical development.[41]

<<<